"Interferon beta-1a" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An interferon beta-1 subtype that has a methionine at position 1, a cysteine at position 17, and is glycosylated at position 80. It functions as an ANTI-VIRAL AGENT and IMMUNOMODULATOR and is used to manage the symptoms of RELAPSING-REMITTING MULTIPLE SCLEROSIS.
| Descriptor ID |
D000068556
|
| MeSH Number(s) |
D12.644.276.374.440.890.275.500 D12.776.467.374.440.890.275.500 D23.529.374.440.890.275.500
|
| Concept/Terms |
Interferon beta-1a- Interferon beta-1a
- beta-1a, Interferon
- Interferon beta 1a
- 1a, Interferon beta
- beta 1a, Interferon
Avonex- Avonex
- Avonex Pen
- Pen, Avonex
|
Below are MeSH descriptors whose meaning is more general than "Interferon beta-1a".
Below are MeSH descriptors whose meaning is more specific than "Interferon beta-1a".
This graph shows the total number of publications written about "Interferon beta-1a" by people in this website by year, and whether "Interferon beta-1a" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 2 | 1 | 3 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 1 | 2 |
| 2020 | 9 | 3 | 12 |
| 2021 | 2 | 5 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Interferon beta-1a" by people in Profiles.
-
Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial. Int Immunopharmacol. 2021 Oct; 99:107969.
-
Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex). CNS Drugs. 2021 07; 35(7):743-767.
-
An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a in severe COVID-19: The COVIFERON II randomized controlled trial. Int Immunopharmacol. 2021 Oct; 99:107916.
-
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-ß-1a and hydroxychloroquine in hospitalized patients with COVID-19. Clin Microbiol Infect. 2021 Dec; 27(12):1826-1837.
-
Reply to Dorgham et al., "Considering Personalized Interferon Beta Therapy for COVID-19". Antimicrob Agents Chemother. 2021 03 18; 65(4).
-
Considering Personalized Interferon Beta Therapy for COVID-19. Antimicrob Agents Chemother. 2021 03 18; 65(4).
-
In inpatients with COVID-19, none of remdesivir, hydroxychloroquine, lopinavir, or interferon ß-1a differed from standard care for in-hospital mortality. Ann Intern Med. 2021 02; 174(2):JC17.
-
The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials. 2021 Jan 04; 22(1):4.
-
Antiviral activity of interferon-based combination therapy in critically ill patients with COVID-19: Preliminary observations. J Glob Antimicrob Resist. 2021 03; 24:124-126.
-
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2021 02 11; 384(6):497-511.